Medicinal Chemistry Research

, Volume 21, Issue 12, pp 4053–4059 | Cite as

Amino acid and peptide esters of abacavir: synthesis and activity against human immunodeficiency virus type 1 in cell culture

  • Ivanka Stankova
  • Kamelia Stanoeva
  • Anton Hinkov
  • Ivailo Alexiev
  • Petya Genova-Kalou
  • Radoslav Chayrov
  • Radka Argirova
Original Research


Abacavir (ABC) is clinically associated with hypersensitivity reactions, risk for cardiovascular disease, etc. A possible way to minimize side effects is by modifying chemical structure. Three esters of ABC containing amino acid (glycine) and dipeptide esters (glycyl-glycine) were synthesized and their activity on HIV-1 III B replication in MT-4 cells was evaluated. One of the newly synthesized esters—Gly-ABC—demonstrates low-cytotoxicity and high-anti-HIV-1 activity in MT-4 cells, as well as low-mitochondrial toxicity and high-genetic barrier to resistance.


Cell culture Aminoacid and dipeptide esters of abacavir Anti-HIV activity Mitochondrial toxicity Sequencing of HIV-mutants 



The financial support of contract VUL-304/07 of Ministry of Science and Education, Republic of Bulgaria, is highly appreciated.

Conflict of interest

The authors declare lack of conflict of interest.


  1. Altmann A, Beerenwinkel N, Sing T et al (2007) Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Therapy 12:169–178Google Scholar
  2. Anand BS, Katragadda S, Mitra AK (2004) Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J Pharmacol Exp Ther 311:659–667PubMedCrossRefGoogle Scholar
  3. Beauchamp M, Orr F, de Miranda P et al (1992) Amino acid ester prodrugs of acyclovir. Antivir Chem Chemother 3:157–164Google Scholar
  4. Brun-Vezinet F, Descamps D, Ruffault A et al (2003) Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17:1795–1802PubMedCrossRefGoogle Scholar
  5. Côté H, Brumme Z, Craib K et al (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346:811–820PubMedCrossRefGoogle Scholar
  6. Harrigan P, Stone C, Griffin P et al (2000) Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CAN 2001 Investigative Group. J Infect Dis 181:912–920PubMedCrossRefGoogle Scholar
  7. Hoffmann C (2010) Drug profiles. In: Hoffmann C, Rockstroh J (eds) HIV 2010 Medizin. Fokus Verlag, Hamburg p 638Google Scholar
  8. Kamps B, Hoffmann C (2007) Drug profiles. In: Hoffmann C, Rockstroh J, Kamps B (eds) HIV medicine 2007, 15th edn. Flying Publisher, Paris, p 706Google Scholar
  9. Kohler J, Hosseini S, Green E et al (2010) Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir. Cardiovasc Toxicol 10:146–151PubMedCrossRefGoogle Scholar
  10. Maggiolo F, Roat E, Pinti M et al (2010) Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Antivir Therapy 15:51–59CrossRefGoogle Scholar
  11. Mallal S, Phillips E, Carosi G et al (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–579PubMedCrossRefGoogle Scholar
  12. Martínez E, Larrousse M, Podzamczer D et al (2010) Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 24:F1–F9PubMedCrossRefGoogle Scholar
  13. Melroy J, Nair V (2005) The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr Pharm Des 11:3847–3852PubMedCrossRefGoogle Scholar
  14. Miró O, López S, Pedrol E et al (2003) Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Therapy 8:333–338Google Scholar
  15. Miró O, López S, Martínez E et al (2004) Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 39:710–716PubMedCrossRefGoogle Scholar
  16. Montefiori D, Robinson W, Schuffmann S et al (1988) Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by rapid and sensitive microtiter infection assay. J Clin Microbiol 26:231–235PubMedGoogle Scholar
  17. Mossman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefGoogle Scholar
  18. Ruiz L, Fuster D, Martinez-Picado J et al. (2005) Genetic barrier. In: Fuster D, Molto J (eds.) Guide to management of HIV drug resistance and antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects, 5th edn., Badalona, p 6 Google Scholar
  19. Schafer J, Short WR, Squires KE (2010) Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy 30:1072–1083PubMedCrossRefGoogle Scholar
  20. Venhoff N, Setzer B, Melkaoui K et al (2007) Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Therapy 12:1075–1085Google Scholar
  21. Walker U, Brinkman K (2001) NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: Fact or fiction? HIV Med 2:163–165PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ivanka Stankova
    • 1
  • Kamelia Stanoeva
    • 2
    • 3
  • Anton Hinkov
    • 3
  • Ivailo Alexiev
    • 4
  • Petya Genova-Kalou
    • 5
  • Radoslav Chayrov
    • 1
  • Radka Argirova
    • 6
  1. 1.Department of ChemistrySouth-West University “Neofit Rilski”BlagoevgradBulgaria
  2. 2.Medical FacultyMedical University of SofiaSofiaBulgaria
  3. 3.Faculty of BiologySofia University “St. Kliment Ohridski”SofiaBulgaria
  4. 4.National HIV Confirmation LaboratoryNational Center of Infectious and Parasitic DiseasesSofiaBulgaria
  5. 5.Lab for Cell CulturesNational Center of Infectious and Parasitic DiseasesSofiaBulgaria
  6. 6.Laboratory of RetrovirusesNational Center for Infectious and Parasitic DiseasesSofiaBulgaria

Personalised recommendations